| Autor: |
Burle-Caldas GA; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil.; Centro de Tecnologia em Vacinas, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Dos Santos NSA; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., de Castro JT; Centro de Tecnologia em Vacinas, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil.; Centro de Pesquisa Rene Rachou, Fundação Osvaldo Cruz, Belo Horizonte, Brazil., Mugge FLB; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Grazielle-Silva V; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Oliveira AER; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Pereira MCA; Centro de Pesquisa Rene Rachou, Fundação Osvaldo Cruz, Belo Horizonte, Brazil., Reis-Cunha JL; Departamento de Parasitologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Dos Santos AC; Departamento de Parasitologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Gomes DA; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Bartholomeu DC; Departamento de Parasitologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil., Moretti NS; Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, Sao Paulo, Brazil., Schenkman S; Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, Sao Paulo, Brazil., Gazzinelli RT; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil.; Centro de Tecnologia em Vacinas, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil.; Centro de Pesquisa Rene Rachou, Fundação Osvaldo Cruz, Belo Horizonte, Brazil., Teixeira SMR; Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil.; Centro de Tecnologia em Vacinas, Universidade Federal de Minas Geraisgrid.8430.f, Belo Horizonte, Brazil. |
| Abstrakt: |
Trans-sialidases (TS) are unusual enzymes present on the surface of Trypanosoma cruzi, the causative agent of Chagas disease. Encoded by the largest gene family in the T. cruzi genome, only few members of the TS family have catalytic activity. Active trans-sialidases (aTS) are responsible for transferring sialic acid from host glycoconjugates to mucins, also present on the parasite surface. The existence of several copies of TS genes has impaired the use of reverse genetics to study this highly polymorphic gene family. Using CRISPR-Cas9, we generated aTS knockout cell lines displaying undetectable levels of TS activity, as shown by sialylation assays and labeling with antibodies that recognize sialic acid-containing mucins. In vitro infection assays showed that disruption of aTS genes does not affect the parasite's capacity to invade cells or to escape from the parasitophorous vacuole but resulted in impaired differentiation of amastigotes into trypomastigotes and parasite egress from the cell. When inoculated into mice, aTS mutants were unable to establish infection even in the highly susceptible gamma interferon (IFN-γ) knockout mice. Mice immunized with aTS mutants were fully protected against a challenge infection with the virulent T. cruzi Y strain. Altogether, our results confirmed the role of aTS as a T. cruzi virulence factor and indicated that aTS play a major role during the late stages of intracellular development and parasite egress. Notably, mutants lacking TS activity are completely avirulent in animal models of infection and may be used as a live attenuated vaccine against Chagas disease. IMPORTANCE Trypanosoma cruzi is the causative agent of Chagas disease, a neglected tropical disease that affects approximately 6 to 8 million people and for which there is no effective treatment or vaccine. The parasite expresses a family of surface proteins, named trans-sialidases, responsible for transferring sialic acid from host glycoconjugates to parasite mucins. Although recognized as a main virulence factor, the multiple roles of these proteins during infection have not yet been fully characterized, mainly because the presence of several copies of aTS genes has impaired their study using reverse genetics. By applying CRISPR-Cas9, we generated aTS knockout parasites and showed that, although aTS parasite mutants were able to infect cells in vitro , they have an impaired capacity to egress from the infected cell. Importantly, aTS mutants lost the ability to cause infection in vivo but provided full protection against a challenge infection with a virulent strain. |
